Australian Drug Foundation have organized a free webinar in Melbourne about new and emerging drugs, that represent one of the biggest challenges in the alcohol and other drug field for 2013 in Australia.
The main goal of the conference is to advocate for and promote harm reduction in the countries of the MENA region and to foster networking between civil society organisations and other stakeholders working in the field.
The UNODC Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme enhances the capacity of Member States in priority regions to generate, manage, analyse, report and use synthetic drug information to design effective policy and programme interventions.
This TNI briefing paper sheds light on the methamphetamine market in Southeast Asia and China, including patterns of supply and use. It highlights the urgent need for donors and governments to introduce effective harm reduction measures aimed at ATS users.
A new report by UNODC ranks amphetamine-type stimulants as the world's second most widely used type of drug after cannabis. Offering the most comprehensive and current analysis of the situation, the 2011 Global ATS Assessment notes that the expansion of the drug's trade and the high criminal…
The Global Drug Survey is an anonymous online survey that addresses how people are using illegal drugs as well as alcohol, tobacco and prescription medications. It combines basic information on what drugs people use, how often they take them, and the medical, social and legal consequences of drug…
The aim of this second TEDI' s report is to present the results of the data that has been gathered, analysed and compared by six harm reduction groups during the seven-month period June–December 2012 in five countries.
Thailand's new Prime Minister, Yingluck Shinawatra, is mobilising a crackdown on illegal drugs as a United Nations agency reveals a massive increase in the production and use of amphetamines across Asia.
This report has been compiled by the EMCDDA in the first half of 2011 as a supporting document for the external evaluation of the 2005–12 EU drugs strategy and its two 2005–08 and 2009–12 action plans.